Impact of Lesion Size on Photodynamic Therapy With Verteporfin of Predominantly Classic Lesions in Age Related Macular Degeneration

British Journal of Ophthalmology - United Kingdom
doi 10.1136/bjo.2004.050997
Full Text
Abstract

Available in full text

Date
Authors
Publisher

BMJ

Related search

Intravitreal Bevacizumab vs Verteporfin Photodynamic Therapy for Neovascular Age-Related Macular Degeneration

Archives of Ophthalmology
2007English

Verteporfin Photodynamic Therapy for Neovascular Age-Related Macular Degeneration: Cohort Study for the UK.

Health Technology Assessment
MedicineHealth Policy
2012English

Photodynamic Therapy for Age-Related Macular Degeneration

The Review of Laser Engineering
2005English

Ranibizumab Versus Verteporfin for Neovascular Age-Related Macular Degeneration

New England Journal of Medicine
Medicine
2006English

Comparative Study of Photodynamic Therapy Monotherapy Versus Triplemanagement in Age-Related Macular Degeneration

Turkish Journal of Medical Sciences
Medicine
2014English

Three-Year Results of a Modified Photodynamic Therapy Procedure (Ironing PDT) for Age-Related Macular Degeneration Patients With Large Lesions

Clinical Ophthalmology
Ophthalmology
2016English

Comparison of the Effect Between Pegaptanib and Ranibizumab on Exudative Age-Related Macular Degeneration With Small Lesion Size

Clinical Ophthalmology
Ophthalmology
2012English

Verteporfin Therapy in Occult With No Classic CNV Due to AMD: Results of the Photodynamic Therapy in Occult-Only Lesions Study

Eye
MedicineArtsSensory SystemsOphthalmologyHumanities
2008English

Changes in Visual Function and Thickness of Macula After Photodynamic Therapy for Age-Related Macular Degeneration

Clinical Ophthalmology
Ophthalmology
2009English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy